Opportunity Information: Apply for PA 18 047
The National Institutes of Health (NIH) funding opportunity titled "Trophoblast Differentiation and Function (R21 Clinical Trial Optional)" (Funding Opportunity Number: PA 18-047) is a discretionary grant program designed to spur innovative, early-stage research on how trophoblast cells develop and function during fertility and pregnancy. The central emphasis is on trophoblast differentiation (how these placental cells form and specialize) and trophoblast function (how they behave and interact with the maternal environment), with explicit interest in understanding how the immune system contributes to healthy implantation and placental development or, conversely, to pregnancy complications. Because trophoblast biology sits at the heart of placental formation and maternal-fetal exchange, the NIH frames this topic as foundational science that can open practical pathways toward better diagnostics, prevention strategies, and treatments.
This FOA is motivated by the idea that many serious pregnancy complications share underlying placental or implantation-related mechanisms that are not yet fully understood. By investing in fundamental and mechanistic research, NIH aims to accelerate progress against placental-based pregnancy disorders, including implantation failure, recurrent or frequent pregnancy loss, preeclampsia, fetal growth restriction, and preterm birth. In other words, the opportunity is positioned to support projects that reveal key biological pathways, cellular behaviors, or immune interactions that shape pregnancy outcomes, with the expectation that clearer mechanisms will ultimately translate into clinical advances.
The mechanism is an R21, which is typically used by NIH to support exploratory or high-impact projects that may be at an earlier stage of development than larger R01-style grants. The "Clinical Trial Optional" designation signals that applicants may propose studies that meet NIH’s definition of a clinical trial, but they are not required to do so; non-clinical basic or translational studies are equally within scope as long as they align with the scientific goals described. The listed award ceiling is $200,000, reflecting the smaller, pilot-oriented nature of the R21 mechanism and its role in helping teams generate compelling proof-of-concept data.
Eligibility is broad, reflecting NIH’s intent to draw ideas from many sectors and institution types. Eligible applicants include a range of government entities (state, county, city or township, special district governments), independent school districts, and public housing authorities/Indian housing authorities. Academic eligibility includes public and state-controlled institutions of higher education as well as private institutions of higher education. The FOA also welcomes nonprofit organizations both with and without 501(c)(3) status (as long as they are not institutions of higher education), for-profit organizations (other than small businesses), and small businesses, along with other applicant types. In addition, the announcement highlights inclusion of organizations that broaden geographic and community representation, such as Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), and Tribally Controlled Colleges and Universities (TCCUs). It also lists Indian/Native American Tribal Governments (other than federally recognized), eligible federal agencies, faith-based or community-based organizations, U.S. territories or possessions, regional organizations, and non-U.S. entities (foreign organizations), signaling an openness to both domestic and international expertise where appropriate.
From an administrative standpoint, the opportunity is categorized as a grant within the Health, Income Security and Social Services activity area, and it is associated with CFDA numbers 93.855, 93.856, and 93.865. The NIH is the sponsoring agency. The source data notes a creation date of 2017-11-15 and an original closing date of 2020-01-07, which is important for applicants to interpret as a historically posted opportunity; anyone looking to apply would typically need to confirm whether the FOA is still active, has been reissued, or has successor announcements with updated dates and requirements.
Overall, this grant opportunity is aimed at researchers who can bring fresh experimental approaches to trophoblast development and placental biology, including maternal immune interactions, to clarify why some pregnancies fail at implantation or develop placental dysfunction later in gestation. By supporting exploratory studies under the R21 framework, NIH is encouraging investigators to test novel hypotheses, develop new models or measurement strategies, and generate the kind of mechanistic evidence that can serve as a springboard for larger studies and, eventually, improved clinical interventions for major pregnancy disorders.Apply for PA 18 047
- The National Institutes of Health in the health, income security and social services sector is offering a public funding opportunity titled "Trophoblast Differentiation and Function (R21 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.855, 93.856, 93.865.
- This funding opportunity was created on 2017-11-15.
- Applicants must submit their applications by 2020-01-07. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $200,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH Trophoblast Differentiation and Function (R21 Clinical Trial Optional) - PA 18-047
What is the name of this NIH funding opportunity?
The funding opportunity is titled "Trophoblast Differentiation and Function (R21 Clinical Trial Optional)" and is associated with Funding Opportunity Number PA 18-047.
What is the main purpose of this grant program?
This program is intended to spur innovative, early-stage research on how trophoblast cells develop (differentiate) and function during fertility and pregnancy. The overall goal is to improve foundational understanding of placental biology and implantation-related mechanisms that can ultimately inform better diagnostics, prevention strategies, and treatments for pregnancy complications.
What scientific areas does the FOA emphasize?
The central emphasis is on two linked areas: (1) trophoblast differentiation, meaning how trophoblast (placental) cells form and specialize, and (2) trophoblast function, meaning how these cells behave and interact with the maternal environment. The FOA also explicitly highlights interest in immune system contributions to healthy implantation and placental development, as well as immune-related pathways that may contribute to pregnancy complications.
Why is trophoblast biology considered important in this opportunity?
Trophoblast biology is framed as foundational because trophoblast cells are central to placental formation and maternal-fetal exchange. NIH positions progress in this area as a pathway to understanding and addressing placental-based pregnancy disorders.
What pregnancy complications is this FOA trying to help address?
The FOA is motivated by the idea that multiple serious pregnancy complications share underlying placental or implantation-related mechanisms that are not yet fully understood. Examples specifically mentioned include implantation failure, recurrent or frequent pregnancy loss, preeclampsia, fetal growth restriction, and preterm birth.
What type of grant mechanism is used?
This opportunity uses the NIH R21 mechanism, which is typically used to support exploratory, innovative, or high-impact projects that may be at an earlier stage than larger R01-style grants.
What does "Clinical Trial Optional" mean in this FOA?
"Clinical Trial Optional" means applicants may propose studies that meet NIH's definition of a clinical trial, but they are not required to do so. Non-clinical basic or translational studies are also within scope as long as they align with the scientific goals described.
What is the award ceiling for this R21 opportunity?
The listed award ceiling is $200,000, reflecting the smaller, pilot-oriented nature of the R21 mechanism and its role in generating proof-of-concept data.
Who is the sponsoring agency?
The sponsoring agency is the National Institutes of Health (NIH).
What activity area is this opportunity categorized under?
It is categorized as a grant within the Health, Income Security and Social Services activity area.
Which CFDA numbers are associated with this opportunity?
The opportunity is associated with CFDA numbers 93.855, 93.856, and 93.865.
Who is eligible to apply?
Eligibility is described as broad and includes multiple organization types across government, academic, nonprofit, and private sectors, including domestic and non-U.S. entities (foreign organizations).
Are academic institutions eligible?
Yes. Eligible academic applicants include public and state-controlled institutions of higher education and private institutions of higher education.
Are nonprofit organizations eligible?
Yes. The FOA welcomes nonprofit organizations both with and without 501(c)(3) status, as long as they are not institutions of higher education.
Are for-profit entities eligible?
Yes. For-profit organizations (other than small businesses) are listed as eligible, and small businesses are also listed as eligible.
Are government entities eligible?
Yes. Eligible government applicants include state governments, county governments, city or township governments, special district governments, independent school districts, and public housing authorities/Indian housing authorities.
Are tribal entities and serving institutions included in eligibility?
Yes. The announcement highlights inclusion of organizations that broaden geographic and community representation, including Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISISs), Hispanic-serving Institutions, Historically Black Colleges and Universities (HBCUs), Tribally Controlled Colleges and Universities (TCCUs), and Indian/Native American Tribal Governments (other than federally recognized).
Are U.S. territories or regional organizations eligible?
Yes. The FOA lists U.S. territories or possessions and regional organizations among eligible applicant types.
Are federal agencies eligible to apply?
Yes. Eligible federal agencies are listed among eligible applicant types.
Are faith-based or community-based organizations eligible?
Yes. Faith-based or community-based organizations are explicitly listed as eligible.
Are non-U.S. (foreign) organizations eligible?
Yes. The opportunity signals openness to non-U.S. entities (foreign organizations) as eligible applicants.
What kinds of projects are a strong fit for this FOA based on the description?
Projects that bring fresh experimental approaches to trophoblast development and placental biology, including maternal immune interactions, are highlighted as aligned. The description emphasizes mechanistic and foundational work that clarifies implantation success or failure and placental dysfunction later in gestation.
Is this opportunity intended for early-stage or proof-of-concept work?
Yes. The R21 mechanism and the stated emphasis on exploratory studies indicate the program is intended to support early-stage, innovative research and generate mechanistic or proof-of-concept evidence that can serve as a springboard for larger studies.
What are the key administrative dates mentioned, and why do they matter?
The source data notes a creation date of 2017-11-15 and an original closing date of 2020-01-07. These dates suggest the posting may be historical, so prospective applicants would typically need to confirm whether the FOA is still active, has been reissued, or has successor announcements with updated dates and requirements.
Does the description indicate whether the FOA is currently open?
No. The information provided includes an original closing date in 2020 and describes it as historically posted, which implies the current status is not confirmed in the provided text.
What is NIH hoping to achieve long-term by funding this research?
NIH frames the long-term impact as advancing fundamental understanding of trophoblast and placental mechanisms so that clearer pathways can eventually translate into clinical advances, including improved diagnostics, prevention strategies, and treatments for major pregnancy disorders.
Browse more opportunities from the same category: Health, Income Security and Social Services
Next opportunity: FY2018 National Network Grant to the National Railroad Passenger Corporation (Amtrak)
Previous opportunity: Cardiovascular and Pulmonary Research on E-Cigarettes (R01)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 18 047
Applicants also applied for:
Applicants who have applied for this opportunity (PA 18 047) also looked into and applied for these:
| Funding Opportunity |
|---|
| Zika Virus (ZIKV) Complications (R21 Clinical Trial Optional) Apply for PA 18 048 Funding Number: PA 18 048 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Oocyte Mitochondrial Function in Relation to Fertility, Aging, and Mitochondrial Diseases (R21 Clinical Trial Optional) Apply for PA 18 093 Funding Number: PA 18 093 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| NCMRR Early Career Research Award (R03 Clinical Trial Optional) Apply for PAR 18 211 Funding Number: PAR 18 211 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $100,000 |
| Human-Animal Interaction (HAI) Research (R01 Clinical Trial Optional) Apply for PAR 18 213 Funding Number: PAR 18 213 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $499,999 |
| Advancing the Science of Multipurpose Technology for the Prevention of HIV and Unintended Pregnancy (R43/R44) Apply for RFA HD 18 102 Funding Number: RFA HD 18 102 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Advancing the Science of Multipurpose Technology for the Prevention of HIV and Unintended Pregnancy (R41/R42) Apply for RFA HD 18 101 Funding Number: RFA HD 18 101 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R21 Clinical Trial Optional) Apply for PAR 18 214 Funding Number: PAR 18 214 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Translational Research in Pediatric and Obstetric Pharmacology and Therapeutics (R01 Clinical Trial Optional) Apply for PAR 18 215 Funding Number: PAR 18 215 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| NICHD Research Education Programs (R25 Clinical Trial Optional) Apply for PAR 18 217 Funding Number: PAR 18 217 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $150,000 |
| NICHD Small Grant Program (R03 - Clinical Trial Optional) Apply for PA 18 481 Funding Number: PA 18 481 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| NICHD Research Project Grant (R01 - Clinical Trial Required) Apply for PA 18 480 Funding Number: PA 18 480 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| NICHD Exploratory/Developmental Research Grant (R21 - Clinical Trial Optional) Apply for PA 18 482 Funding Number: PA 18 482 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| The Role of Stem/Progenitor Cells in the Pathogenesis and Treatment of Gynecologic Disorders (R01 - Clinical Trial Optional) Apply for RFA HD 19 013 Funding Number: RFA HD 19 013 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $499,999 |
| Studies in Neonatal and Pediatric Resuscitation (R01 Clinical Trial Optional) Apply for PA 18 485 Funding Number: PA 18 485 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Studies in Neonatal and Pediatric Resuscitation (R03 - Clinical Trial Optional) Apply for PA 18 491 Funding Number: PA 18 491 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $50,000 |
| Non-Invasive Diagnostics to Improve Gynecologic Health (R43/R44 - Clinical Trial Optional) Apply for RFA HD 19 006 Funding Number: RFA HD 19 006 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Drug Repurposing for Conditions Affecting Neonates and Pregnant Women (R01 - Clinical Trial Optional) Apply for PAR 18 506 Funding Number: PAR 18 506 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Discovery of Molecular Targets for Pregnancy-Related/Induced Diseases and Development of Therapeutics to Prevent/Treat These Diseases (R01 - Clinical Trial Optional) Apply for PAR 18 511 Funding Number: PAR 18 511 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: Case Dependent |
| Human-Animal Interaction (HAI) Research (R21 - Clinical Trial Optional) Apply for PAR 18 650 Funding Number: PAR 18 650 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $200,000 |
| Human-Animal Interaction (HAI) Research (R03 - Clinical Trial Optional) Apply for PAR 18 649 Funding Number: PAR 18 649 Agency: National Institutes of Health Category: Health, Income Security and Social Services Funding Amount: $50,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 18 047", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.